Dopaminergic system, reportedly known to directly modulate GH synthesis and release at the pituitary level (49), has been proposed as one of the neurotransmitter systems implicated in the development and interplay of sleep disorders and depression (48), and dopaminergic agents are currently used in clinical practice to treat daytime sleepiness and sleep disorders (48). Here, GH1 is linked to depressive symptom measurement.